Retatrutide Dosage Guide: How Much to Take, How Often, and For How Long (2026)

Important: We are not doctors. Everything in this article is based on published research and publicly available clinical data. It is not medical advice. Talk to your physician before changing any medication or health protocol.

---

Retatrutide Dosage: How Much to Take, How Often, and For How Long

In clinical trials, researchers started retatrutide at 2mg once weekly and titrated up to 12mg over several months. The 12mg dose produced the most weight loss: 24.2% at 48 weeks in Phase 2 (Jastreboff et al., 2023) and 28.7% at 68 weeks in Phase 3 TRIUMPH-4. But more is not automatically better. The 8mg dose produced 22.8% weight loss with fewer side effects. Here is everything the published research shows about retatrutide dosing.

---

The Bottom Line

• Retatrutide is not available yet. It is still in clinical trials (Phase 3) and has not been approved by the FDA.
• In trials, researchers tested doses from 1mg to 12mg, given once a week by injection.
• The 12mg dose showed the biggest weight loss results: about 24% at 48 weeks and nearly 29% at 68 weeks. The 8mg dose was close behind at about 23%, with fewer side effects.
• You cannot get a real prescription for retatrutide right now. Anything sold online as "retatrutide" is unregulated and unverified.
• The earliest it could hit the market is late 2027 or 2028, depending on how the remaining trials go and when Eli Lilly files for FDA approval.

---

Key Takeaways

• Retatrutide is administered as a once-weekly subcutaneous injection
• Clinical trial doses ranged from 1mg to 12mg, with 8mg and 12mg producing the largest weight loss
• Starting dose in most trial arms was 2mg, titrating up every 4 weeks
• The 12mg dose produced 24.2% weight loss at 48 weeks (Phase 2) and 28.7% at 68 weeks (Phase 3)
• Slower titration (starting at 2mg vs 4mg) significantly reduced nausea and GI side effects
• Retatrutide is NOT FDA-approved. It is currently in Phase 3 clinical trials (Eli Lilly, TRIUMPH program)
• Talk to your physician before starting any weight loss medication

---

What the Clinical Trials Used

Phase 2 Obesity Trial Dosage Chart

This is the primary dosage data from the landmark Phase 2 trial published in the New England Journal of Medicine. 338 adults with obesity were randomized to different dose levels for 48 weeks (Jastreboff et al., 2023).

Dose Group	Starting Dose	Target Dose	Frequency	Duration
Low	1mg	1mg (no escalation)	Once weekly	48 weeks
Medium (slow)	2mg	4mg	Once weekly	48 weeks
Medium (fast)	4mg	4mg (no escalation)	Once weekly	48 weeks
High (slow)	2mg	8mg	Once weekly	48 weeks
High (fast)	4mg	8mg	Once weekly	48 weeks
Maximum (slow)	2mg	12mg	Once weekly	48 weeks
Placebo	--	--	Once weekly	48 weeks

The "slow" groups started at 2mg and titrated up over several weeks. The "fast" groups started at 4mg. This distinction matters because the starting dose directly affected how many people experienced nausea and other GI symptoms.

Phase 3 TRIUMPH-4 Dosage (2026)

The TRIUMPH-4 trial tested 9mg and 12mg in 445 adults with obesity and knee osteoarthritis for 68 weeks. Participants started at a lower dose and titrated up, consistent with the Phase 2 slow-escalation approach.

Dose Group	Target Dose	Frequency	Duration	Weight Loss
9mg	9mg	Once weekly	68 weeks	~26%
12mg	12mg	Once weekly	68 weeks	28.7% (avg 71.2 lbs)
Placebo	--	Once weekly	68 weeks	~2%

Source: Eli Lilly press release, 2026

Phase 3 TRANSCEND-T2D-1 Dosage (March 2026)

The most recent data, released March 2026, tested retatrutide in adults with type 2 diabetes over 40 weeks.

Dose Group	A1C Reduction	Weight Loss	Duration
Lower doses	-1.7%	Data pending	40 weeks
12mg	-2.0%	16.8% (avg 36.6 lbs)	40 weeks
Placebo	Minimal	Minimal	40 weeks

Note: Weight loss was lower in the T2D population (16.8% vs 28.7%), which is consistent across all GLP-1 class medications. People with type 2 diabetes typically lose less weight on the same doses. No weight loss plateau was observed at 40 weeks, meaning participants were still losing.

---

Titration: Why Starting Low Matters

The Phase 2 trial had a built-in experiment: some groups started at 2mg ("slow escalation") and others started at 4mg ("fast escalation"). The results are clear.

Starting at 2mg produced fewer GI side effects than starting at 4mg. The final weight loss was the same. There was no benefit to starting higher. The body needs time to adjust to triple receptor activation.

A reasonable titration based on the trial protocols:

Week	Dose	Notes
Weeks 1-4	2mg	Starting dose. Assess tolerance.
Weeks 5-8	4mg	First escalation. GI symptoms may increase.
Weeks 9-12	8mg	Second escalation. Most therapeutic benefit begins here.
Weeks 13-16	12mg	Maximum dose. Only if 8mg is well-tolerated.
Weeks 17+	8-12mg	Maintenance. Dose depends on response and tolerability.

This schedule is reconstructed from the Phase 2 and Phase 3 trial designs. Your physician will determine the actual titration based on your individual response.

What Happens If You Titrate Too Fast

In the Phase 2 trial, participants who started at 4mg (fast escalation) experienced more nausea and vomiting than those who started at 2mg. The weight loss at 48 weeks was not meaningfully different between the two groups.

The takeaway: patience during titration pays off. Rushing the dose increase gains you nothing except more time over the toilet.

---

Weight Loss by Dose: The Actual Numbers

Phase 2 Results at 48 Weeks

Dose	Weight Loss (%)	5%+ Loss	10%+ Loss	15%+ Loss
1mg	-8.7%	--	--	--
4mg (combined)	-17.1%	92%	75%	60%
8mg (combined)	-22.8%	100%	91%	75%
12mg	-24.2%	100%	93%	83%
Placebo	-2.1%	27%	9%	2%

Source: Jastreboff et al., NEJM 2023

The jump from 8mg to 12mg added 1.4 percentage points of weight loss (22.8% vs 24.2%) while increasing side effects. For many people, 8mg may be the sweet spot. This is a conversation to have with your doctor.

Phase 3 Results at 68 Weeks

TRIUMPH-4 showed 28.7% weight loss with 12mg at 68 weeks. That is an average of 71.2 pounds. It is the largest weight loss reported in any obesity drug trial to date.

How Retatrutide Compares

Compound	Max Dose	Best Weight Loss	Duration	Trial
Retatrutide	12mg weekly	28.7%	68 weeks	TRIUMPH-4 (Phase 3)
Tirzepatide	15mg weekly	22.5%	72 weeks	SURMOUNT-1
Semaglutide	2.4mg weekly	14.9%	68 weeks	STEP 1
Semaglutide	7.2mg weekly	20.7%	72 weeks	STEP UP
Liraglutide	3.0mg daily	5.8%	26 weeks	SCALE

For full comparisons, see our retatrutide vs tirzepatide and retatrutide vs semaglutide guides.

---

How Long to Take It

What the Studies Show

The Phase 2 trial ran for 48 weeks. The Phase 3 TRIUMPH-4 trial ran for 68 weeks. The TRANSCEND-T2D-1 trial reported at 40 weeks with no weight loss plateau observed. That means participants were still losing weight when the data was cut.

No published data exists on retatrutide use beyond 68 weeks. Longer-term Phase 3 trials are ongoing and expected to report later in 2026.

What Happens When You Stop

No published discontinuation data exists for retatrutide specifically. However, every GLP-1 class medication studied to date shows significant weight regain after stopping. In the STEP 1 extension trial, participants regained approximately two-thirds of their lost weight within one year of stopping semaglutide.

There is no reason to believe retatrutide would be different. The weight loss depends on continued receptor activation. Stop the drug, the appetite returns, the weight follows.

This is not a criticism of the medication. It is how the biology works. Obesity is a chronic condition that requires ongoing treatment, the same way blood pressure medication manages hypertension.

Cycling

Retatrutide is not a research peptide you cycle on and off. It is a pharmaceutical compound designed for continuous use under medical supervision. There is no published evidence supporting cycling protocols, and no receptor desensitization has been observed in trials up to 68 weeks.

---

Side Effects by Dose

Phase 2 Adverse Events

Side Effect	1mg	4mg	8mg	12mg	Placebo
Any GI event	Low	Moderate	Moderate-High	High	Low
Nausea	Mild	Moderate	Moderate	Dose-related	~6%
Diarrhea	Mild	Mild	Moderate	Moderate	Low
Vomiting	Rare	Mild	Moderate	Moderate	Rare
Constipation	Mild	Mild	Mild	Mild	Low
Heart rate increase	Minimal	Mild	Moderate	Moderate	None

GI adverse events were mostly mild to moderate and occurred primarily during dose escalation. They tended to improve after the body adjusted to each new dose level. The heart rate increase peaked at 24 weeks and declined afterward (Jastreboff et al., 2023).

Phase 3 TRANSCEND-T2D-1 Side Effects

Side Effect	Retatrutide (range across doses)	Placebo
Nausea	18.7-26.3%	3.7%
Diarrhea	18.7-26.3%	4.5%
Vomiting	15.7-17.6%	2.2%

These occurred primarily during dose escalation and were consistent with the GLP-1 receptor agonist class.

A New Safety Signal

BioSpace reported that TRIUMPH-4 identified a new safety signal, though full details have not yet been published in a peer-reviewed journal. This is worth discussing with your physician as more data becomes available.

Managing Side Effects

Based on clinical trial data and the GLP-1 class broadly:

1. Start low, titrate slow. The 2mg starting dose reduced GI events compared to 4mg. There is no weight loss penalty for going slower.
2. Eat smaller meals. Large, high-fat meals worsen nausea because retatrutide slows gastric emptying.
3. Stay hydrated. Diarrhea and vomiting increase dehydration risk, especially during escalation.
4. Give each dose level 4 weeks. Do not rush escalation to chase faster results. Your body needs adaptation time.

---

Body Composition: Fat vs. Muscle Loss

A common concern with weight loss medications is losing muscle along with fat. A Phase 2 substudy using DXA scans directly measured this (Coskun et al., 2025).

Dose	Total Fat Mass Reduction	vs Placebo
4mg (combined)	-15.2%	-10.7%
8mg (combined)	-26.1%	-21.6%
12mg	-23.2%	-18.7%

The proportion of lean mass lost relative to total weight lost was similar to other obesity medications. Retatrutide did not cause disproportionate muscle wasting despite the greater overall weight loss. Resistance training during treatment is still recommended to preserve lean mass.

---

How Retatrutide Works (Why Three Receptors Matter)

Retatrutide is a triple agonist. It activates three receptors simultaneously:

1. GLP-1 receptor: Reduces appetite, slows gastric emptying, improves insulin secretion. This is the same mechanism as semaglutide and tirzepatide.
2. GIP receptor: Enhances the GLP-1 effect on appetite and insulin. This is shared with tirzepatide but not semaglutide.
3. Glucagon receptor: Increases energy expenditure and promotes fat oxidation in the liver. This is unique to retatrutide.

The glucagon component is what separates retatrutide from everything else on the market. It adds a direct fat-burning signal on top of the appetite suppression. This is likely why retatrutide produced greater weight loss than tirzepatide (which only hits GLP-1 and GIP) and semaglutide (which only hits GLP-1).

It also explains the liver fat reduction. In Phase 2 substudies, retatrutide reduced liver fat by up to 82% in participants with metabolic dysfunction-associated steatotic liver disease (MASLD). Glucagon receptor activation drives hepatic fat oxidation directly.

---

FDA Status and Availability

Retatrutide is not FDA-approved. It is in Phase 3 clinical trials under the TRIUMPH (obesity) and TRANSCEND (type 2 diabetes) programs, both sponsored by Eli Lilly.

Polymarket currently prices FDA approval this year at 22% probability (as of March 2026). Seven additional Phase 3 trials are expected to complete in 2026, with an FDA submission likely in 2027 at the earliest.

Can You Get Retatrutide Now?

Retatrutide is not available through any legitimate pharmacy or telehealth provider. It has not been approved for compounding. Any product sold as "retatrutide" online is from the gray market research chemical supply chain.

We do not recommend purchasing unregulated peptides. The purity, dosing accuracy, and sterility of gray market products cannot be verified. If you are interested in retatrutide, talk to your physician about clinical trial enrollment at ClinicalTrials.gov.

For FDA-approved alternatives with similar mechanisms, see our guides on tirzepatide dosage and semaglutide dosage.

---

Frequently Asked Questions

How much retatrutide should I take for weight loss?

In the Phase 2 obesity trial, researchers administered doses ranging from 1mg to 12mg once weekly. The 8mg and 12mg doses produced the most weight loss (22.8% and 24.2% at 48 weeks, respectively). The Phase 3 TRIUMPH-4 trial used 9mg and 12mg doses. Your physician will determine the appropriate dose based on your response and tolerability.

How long does it take for retatrutide to work?

In clinical trials, meaningful weight loss was already apparent at 24 weeks. At that point, participants on 12mg had lost an average of 17.5% of their body weight. Weight loss continued through 48 and 68 weeks without plateauing. Most participants experienced some GI side effects in the first 4-8 weeks during dose escalation, with improvement afterward.

Is retatrutide better than tirzepatide or semaglutide?

In clinical trials, retatrutide produced greater weight loss than both. At 48 weeks, retatrutide 12mg produced 24.2% weight loss compared to tirzepatide 15mg at 22.5% (72 weeks) and semaglutide 2.4mg at 14.9% (68 weeks). However, these are cross-trial comparisons, not head-to-head studies. Direct comparison trials have not been conducted. Retatrutide also had a higher adverse event rate.

When will retatrutide be FDA-approved?

Phase 3 trials are ongoing. Seven trials are expected to complete in 2026, with an FDA submission likely in 2027 at the earliest. Approval, if granted, would follow the submission by approximately 10-12 months. A realistic timeline for availability is late 2027 or 2028.

Can I take retatrutide with other medications?

No published interaction data exists for retatrutide specifically. However, because it slows gastric emptying (like all GLP-1 agonists), it may affect the absorption of oral medications. This is especially important for oral contraceptives, thyroid medications, and diabetes medications. Discuss all current medications with your physician.

How is retatrutide injected?

Retatrutide is administered as a subcutaneous (under the skin) injection once weekly. In clinical trials, injection sites included the abdomen, thigh, or upper arm. The injection site should be rotated each week.

---

References

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315

2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. PMID: 37385280

3. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2 trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684. PMID: 40609566

4. Sinha B, Ghosal S. Efficacy and safety of GLP-1 receptor agonists, dual agonists, and retatrutide for weight loss in adults with overweight or obesity: a Bayesian NMA. Obesity. 2025;33(11):2046-2054. PMID: 40685589

5. Moiz A, Filion KB, Toutounchi H, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review. Ann Intern Med. 2025;178(2):199-217. PMID: 39761578

6. Eli Lilly. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Press release, 2026

7. Eli Lilly. Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes. Press release, March 2026

8. ClinicalTrials.gov. TRIUMPH-4: A Study of Retatrutide (LY3437943) Once Weekly in Participants With Obesity and Knee Osteoarthritis. NCT05931367